ADDPLAN DF Consortium
At a Glance
- Status: Active Consortium
- Year Launched: 2013
- Initiating Organization: ICON plc
- Initiator Type: Industry
- No disease focus
- Location: North America
ADDPLAN® is a stand-alone software, using data to design, simulate, and analyze adaptive clinical trials with ease. The ADDPLAN DF Consortium is comprised of Novartis Pharma AG, Janssen Pharmaceuticals Inc., Eli Lilly, and Aptiv Solutions. The consortium’s objective is to deliver a comprehensive platform and process map for the integrated design and execution of innovative exploratory phase adaptive trials.
The consortium will work collaboratively to address the challenges that arise in phases II and III of pharmaceutical trials by:
-Developing new statistical methodologies for the design of innovative dose-finding clinical trials with an emphasis on adaptive designs
-Focusing on enhancing the trial execution technologies required to handle the multiple adaptations integral to complex adaptive dose-finding trials
-Integrating and validating these methodologies into ADDPLAN DF software for the design, planning, and analysis of dose finding trials, and ensuring that these designs are easily implemented through AptivAdvantage™, the Aptiv Solutions proprietary trial execution platform
ADDPLAN DF Consortium was founded in 2013
Structure & Governance
ADDPLAN is adaptive trail design software developed by ICON, a global provider of outsourced drug development services to biopharma, medical device, government, biosimilar, and genetic organizations.
Points of Contact
Director of Corporate Communications
Sponsors & Partners
ICON plc (Sponsor)
Novartis Pharma AG
Janssen Pharmaceuticals Inc.